News

The Marijuana Herald7m
Clinical Trial: Topical CBD Gel Reduces Migraines and Improves Sleep in People With Bruxism-Related Muscle Pain
A new clinical trial conducted by researchers at the Medical University of Silesia in Katowice found that topical cannabidiol ...
Targeted Oncology17m
CLD-201 Receives FDA Fast Track Designation Targeting Sarcoma
FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and ...
The American Journal of Managed Care19m
Apremilast Maintains Efficacy at 2 Years in Pediatric Psoriasis
In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and ...
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...
MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...
The Malaysian Reserve52m
CereVasc, Inc. Announces 100th Patient Treated with the eShunt® System
Patient treated at Clinica la Sagrada Familia in Buenos Aires, Argentina BOSTON, July 30, 2025 /PRNewswire/ -- CereVasc, Inc.
Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector
Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and ...
The Malaysian Reserve1h
EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
This IND clearance represents a major milestone for EuMentis as we advance EM–221 through Phase 2 clinical development,” said ...